Early-stage triple-negative breast cancer Book Section
| Authors: | Traina, T. A.; dos Anjos, C.; Walsh, E. |
| Editors: | Abutalib, S. A.; Markman, M.; Benson, A. B. 3rd; Rugo, H. S. |
| Article/Chapter Title: | Early-stage triple-negative breast cancer |
| Abstract: | This chapter provides answers to practice-based questions with case studies covering the new principles of diagnosis, classification, staging, treatment, and outcomes in the rapidly advancing field of triple-negative breast cancer (TNBC). TNBC is a subtype of breast cancers that do not express estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2. In the early stage setting, TNBC is treated according to tumor stage, and treatment typically consists of both local and systemic therapy given to reduce risk of recurrence and improve survival. Therapeutic advances in the fields of immunotherapy and targeted therapy have changed the treatment landscape for a subset of patients with early stage TNBC. The chapter also provides expert guidance in the areas of cancer-related uncertainties and controversies, including experience-based discussions. © 2024 John Wiley & Sons Ltd. |
| Keywords: | immunotherapy; estrogen receptor; progesterone receptor; human epidermal growth factor receptor 2; triple-negative breast cancer |
| Book Title: | Cancer Consult: Expertise in Clinical Practice. 2nd ed |
| Volume: | 1 |
| ISBN: | 9781119823735 |
| Publisher: | Wiley Blackwell |
| Publication Place: | Hoboken, NJ |
| Date Published: | 2024-01-01 |
| Start Page: | 179 |
| End Page: | 190 |
| Language: | English |
| DOI: | 10.1002/9781119823766.ch15 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book Chapter: 15, in "Part 3: Breast Cancer" -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work